Type 2 diabetes mellitus (DM2) affects a 13.8% of the Spanish population1 and its prevalence is expected to increase in the future.2 The presence of DM2 increases significantly the risk of cardiovascular events, chronic kidney disease (CKD), and premature death3,4 and as its prevalence increases it is expected to rise the incidence of microvascular and macrovascular complications.5 Until the last decade, the control of blood glucose, blood pressure, dyslipidemia, and the use of inhibitors of the renin-angiotensin system (iSRA) have been the only strategies available to reduce cardiovascular and renal risk in this population
If you are ready to try peptides for weight loss, get started by using our virtual consultation tool or by scheduling an appointment online.
This makes dosing straightforward with a standard insulin syringe where 5 units equals 0.1 mg
This peptide is a master of regeneration, and its work extends to other parts of the body that show signs of aging or wear and tear
We look at what real patients are saying across the internet to assess each clinic based on user experience
Wegovy should not be used in combination with other GLP-1 receptor agonists or other semaglutide-containing products